Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2012

Open Access 01-12-2012 | Research article

Inflammatory gene variants and the risk of biliary tract cancers and stones: a population-based study in China

Authors: Felipe A Castro, Jill Koshiol, Ann W Hsing, Yu-Tang Gao, Asif Rashid, Lisa W Chu, Ming-Chang Shen, Bing-Shen Wang, Tian-Qua Han, Bai-He Zhang, Shelley Niwa, Kai Yu, Hong Zhang, Stephen Chanock, Gabriella Andreotti

Published in: BMC Cancer | Issue 1/2012

Login to get access

Abstract

Background

Genetic variants in inflammation-related genes have been associated with biliary stones and biliary tract cancers in previous studies.

Methods

To follow-up on these findings, we examined 35 single nucleotide polymorphism (SNPs) in 5 genes related to inflammation (IL8, NFKBIL, RNASEL, TNF, and VEGFA) in 456 participants with incident biliary tract cancer cases (262 gallbladder, 141 extrahepatic bile duct, 53 ampulla of Vater), 982 participants with biliary stones, and 860 healthy controls in a population–based case–control study in Shanghai, China.

Results

Suggestive associations were observed for SNPs in VEGFA with biliary stones, IL8 with gallbladder and ampulla of Vater cancers, and RNASEL with ampulla of Vater cancer (false discovery rate≤0.2).

Conclusion

These findings provide additional support for the role of inflammation in biliary stones and biliary tract cancer risk and need further validation.
Appendix
Available only for authorised users
Literature
1.
Randi G, Malvezzi M, Levi F, Ferlay J, Negri E, Franceschi S, La Vecchia C: Epidemiology of biliary tract cancers: an update. Ann Oncol. 2009, 20 (1): 146-159.CrossRefPubMed
2.
Hsing A, Rashid A, Devesa S, Fraumeni JJ: Biliary Tract Cancer. Cancer Epidemiology and Prevention. Edited by: Jr DSJF. 2006, New York: Oxford University Press, Inc, 787-800. Third EditionCrossRef
3.
Hsing AW, Gao YT, Han TQ, Rashid A, Sakoda LC, Wang BS, Shen MC, Zhang BH, Niwa S, Chen J, et al: Gallstones and the risk of biliary tract cancer: a population-based study in China. Br J Cancer. 2007, 97 (11): 1577-1582. 10.1038/sj.bjc.6604047.CrossRefPubMedPubMedCentral
4.
Hsing AW, Gao YT, McGlynn KA, Niwa S, Zhang M, Han TQ, Wang BS, Chen J, Sakoda LC, Shen MC, et al: Biliary tract cancer and stones in relation to chronic liver conditions: A population-based study in Shanghai, China. Int J Cancer. 2007, 120 (9): 1981-1985. 10.1002/ijc.22375.CrossRefPubMed
5.
Hsing AW, Zhang M, Rashid A, McGlynn KA, Wang BS, Niwa S, Ortiz-Conde BA, Goedert JJ, Fraumeni JF, O'Brien TR, et al: Hepatitis B and C virus infection and the risk of biliary tract cancer: a population-based study in China. Int J Cancer. 2008, 122 (8): 1849-1853.CrossRefPubMed
6.
Liu E, Sakoda LC, Gao YT, Rashid A, Shen MC, Wang BS, Deng J, Han TQ, Zhang BH, Fraumeni JF, et al: Aspirin use and risk of biliary tract cancer: a population-based study in Shanghai, China. Cancer Epidemiol Biomarkers Prev. 2005, 14 (5): 1315-1318. 10.1158/1055-9965.EPI-05-0032.CrossRefPubMed
7.
Vishnoi M, Pandey SN, Choudhuri G, Mittal B: IL-1 gene polymorphisms and genetic susceptibility of gallbladder cancer in a north Indian population. Cancer Genet Cytogenet. 2008, 186 (2): 63-68. 10.1016/j.cancergencyto.2008.05.004.CrossRefPubMed
8.
Vishnoi M, Pandey SN, Choudhury G, Kumar A, Modi DR, Mittal B: Do TNFA −308 G/A and IL6–174 G/C gene polymorphisms modulate risk of gallbladder cancer in the north Indian population?. Asian Pac J Cancer Prev. 2007, 8 (4): 567-572.PubMed
9.
Srivastava A, Pandey SN, Choudhuri G, Mittal B: CCR5 Delta32 polymorphism: associated with gallbladder cancer susceptibility. Scand J Immunol. 2008, 67 (5): 516-522. 10.1111/j.1365-3083.2008.02097.x.CrossRefPubMed
10.
Sakoda LC, Gao YT, Chen BE, Chen J, Rosenberg PS, Rashid A, Deng J, Shen MC, Wang BS, Han TQ, et al: Prostaglandin-endoperoxide synthase 2 (PTGS2) gene polymorphisms and risk of biliary tract cancer and gallstones: a population-based study in Shanghai, China. Carcinogenesis. 2006, 27 (6): 1251-1256. 10.1093/carcin/bgi314.CrossRefPubMed
11.
Hsing AW, Sakoda LC, Rashid A, Andreotti G, Chen J, Wang BS, Shen MC, Chen BE, Rosenberg PS, Zhang M, et al: Variants in inflammation genes and the risk of biliary tract cancers and stones: a population-based study in China. Cancer Res. 2008, 68 (15): 6442-6452. 10.1158/0008-5472.CAN-08-0444.CrossRefPubMedPubMedCentral
12.
Ghosh S, May MJ, Kopp EB: NF-kappa B and Rel proteins: evolutionarily conserved mediators of immune responses. Annu Rev Immunol. 1998, 16: 225-260. 10.1146/annurev.immunol.16.1.225.CrossRefPubMed
13.
14.
Benjamini Y, Drai D, Elmer G, Kafkafi N, Golani I: Controlling the false discovery rate in behavior genetics research. Behav Brain Res. 2001, 125 (1–2): 279-284.CrossRefPubMed
15.
Han S, Lee KM, Park SK, Lee JE, Ahn HS, Shin HY, Kang HJ, Koo HH, Seo JJ, Choi JE, et al: Genome-wide association study of childhood acute lymphoblastic leukemia in Korea. Leuk Res. 2010, 34 (10): 1271-1274. 10.1016/j.leukres.2010.02.001.CrossRefPubMed
16.
Barry KH, Koutros S, Andreotti G, Sandler DP, Burdette LA, Yeager M, Beane Freeman LE, Lubin JH, Ma X, Zheng T, et al: Genetic variation in nucleotide excision repair pathway genes, pesticide exposure and prostate cancer risk. Carcinogenesis. 2011, 33 (2): 331-337.CrossRefPubMedPubMedCentral
17.
Westfall PH, Young SS: Resampling-Based Multiple Testing: Examples and Methods for p-Value Adjustment. 1993, New York: John Wiley & Sons
18.
19.
Castelli J, Wood KA, Youle RJ: The 2-5A system in viral infection and apoptosis. Biomed Pharmacother. 1998, 52 (9): 386-390. 10.1016/S0753-3322(99)80006-7.CrossRefPubMed
20.
Wiklund F, Jonsson BA, Brookes AJ, Stromqvist L, Adolfsson J, Emanuelsson M, Adami HO, Augustsson-Balter K, Gronberg H: Genetic analysis of the RNASEL gene in hereditary, familial, and sporadic prostate cancer. Clin Cancer Res. 2004, 10 (21): 7150-7156. 10.1158/1078-0432.CCR-04-0982.CrossRefPubMed
21.
Madsen BE, Ramos EM, Boulard M, Duda K, Overgaard J, Nordsmark M, Wiuf C, Hansen LL: Germline mutation in RNASEL predicts increased risk of head and neck, uterine cervix and breast cancer. PLoS One. 2008, 3 (6): e2492-10.1371/journal.pone.0002492.CrossRefPubMedPubMedCentral
22.
Xie K: Interleukin-8 and human cancer biology. Cytokine Growth Factor Rev. 2001, 12 (4): 375-391. 10.1016/S1359-6101(01)00016-8.CrossRefPubMed
23.
Andreotti G, Liu E, Gao YT, Safaeian M, Rashid A, Shen MC, Wang BS, Deng J, Han TQ, Zhang BH, et al: Medical history and the risk of biliary tract cancers in Shanghai, China: implications for a role of inflammation. Cancer Causes Control. 2011, 22 (9): 1289-1296. 10.1007/s10552-011-9802-z.CrossRefPubMed
24.
Maurer KJ, Carey MC, Fox JG: Roles of infection, inflammation, and the immune system in cholesterol gallstone formation. Gastroenterology. 2009, 136 (2): 425-440. 10.1053/j.gastro.2008.12.031.CrossRefPubMed
25.
Tazuma S, Kajiyama G: Carcinogenesis of malignant lesions of the gall bladder. The impact of chronic inflammation and gallstones. Langenbeck's archives of surgery / Deutsche Gesellschaft fur Chirurgie. 2001, 386 (3): 224-229. 10.1007/s004230100220.CrossRefPubMed
26.
Spirli C, Nathanson MH, Fiorotto R, Duner E, Denson LA, Sanz JM, Di Virgilio F, Okolicsanyi L, Casagrande F, Strazzabosco M: Proinflammatory cytokines inhibit secretion in rat bile duct epithelium. Gastroenterology. 2001, 121 (1): 156-169. 10.1053/gast.2001.25516.CrossRefPubMed
27.
Rotival M, Zeller T, Wild PS, Maouche S, Szymczak S, Schillert A, Castagne R, Deiseroth A, Proust C, Brocheton J, et al: Integrating genome-wide genetic variations and monocyte expression data reveals trans-regulated gene modules in humans. PLoS Genet. 2011, 7 (12): e1002367-10.1371/journal.pgen.1002367.CrossRefPubMedPubMedCentral
28.
Freedman ML, Monteiro AN, Gayther SA, Coetzee GA, Risch A, Plass C, Casey G, De Biasi M, Carlson C, Duggan D, et al: Principles for the post-GWAS functional characterization of cancer risk loci. Nat Genet. 2011, 43 (6): 513-518. 10.1038/ng.840.CrossRefPubMedPubMedCentral
Metadata
Title
Inflammatory gene variants and the risk of biliary tract cancers and stones: a population-based study in China
Authors
Felipe A Castro
Jill Koshiol
Ann W Hsing
Yu-Tang Gao
Asif Rashid
Lisa W Chu
Ming-Chang Shen
Bing-Shen Wang
Tian-Qua Han
Bai-He Zhang
Shelley Niwa
Kai Yu
Hong Zhang
Stephen Chanock
Gabriella Andreotti
Publication date
01-12-2012
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2012
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-12-468

Other articles of this Issue 1/2012

BMC Cancer 1/2012 Go to the issue

Research article

Mortality in cancer patients with a history of cutaneous squamous cell carcinoma - a nationwide population-based cohort study

Research article

Deletion of the TNFAIP3/A20gene detected by FICTION analysis in classical Hodgkin lymphoma

Research article

Expression of ERBB3 binding protein 1 (EBP1) in salivary adenoid cystic carcinoma and its clinicopathological relevance

Research article

Knock-down of NDRG2 sensitizes cervical cancer Hela cells to cisplatin through suppressing Bcl-2 expression

Research article

Aquaporin 3 (AQP3) participates in the cytotoxic response to nucleoside-derived drugs

Research article

Obesity, body composition, and prostate cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits